head of Lilly Oncology. The agreement isn't Lilly's first attempt to make a mark in the PI3K inhibitor class, having previously been working on LOXO-783, a drug it acquired as part of its $8 ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Behind Lilly's decline ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY -3.19%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...